sequelae of chronic, refractory epilepsy, avoided. This concept dovetailed with the 2001 publication of the first randomized controlled trial of epilepsy surgery (3) , which was central to the 2003 AAN epilepsy surgery practice parameter (4) . Consideration of early epilepsy surgery in patients with DRE has been encouraged, and this approach has been supported by subsequent work (5) .
This apparently grim outlook for further medical therapy in patients with new-onset epilepsy, who had failed 2 to 3 medication trials, might be presumed to be similar or worse in a population of patients with existing DRE, but study of this population has revealed a more complex picture.
The earliest study of DRE cohorts was in children, but by 2007, some larger studies in adult populations were appearing (6, 7) . These retrospective studies of patients with chronic refractory epilepsy, who were experiencing at least 1 seizure per month on antiseizure therapy, surprisingly found that 15 to 16 percent of patients entered seizure remission for 6 or 12 months (depending on the study), and that on average, 4 to 5 percent of this population entered remission each year. Some variables that predicted response to continued medication trials were identified, and a glimmer of hope was seen even in this chronic, previously drug-resistant population. However, OBJECTIVE: To examine the seizure trajectories of adults with epilepsy developing drug-resistant epilepsy (DRE) and to identify the predictors of seizure trajectory outcome. METHODS: Adult patients failing two antiepileptic drugs (AEDs) due to inefficacy and starting their third AED at a tertiary epilepsy center were followed for seizure trajectory outcome during medical management. Seizure trajectories were categorized into one of four patterns: (1) course with constant seizures; (2) fluctuating course; (3) delayed attainment of seizure freedom (seizure freedom delayed for >12 months after start of the study, but patient stayed in seizure freedom); and (4) early attainment of seizure freedom (within 12 months of starting study). Multiple ordinal logistic regression models were used to estimate the association between trajectory categories and clinical factors. RESULTS: Four hundred three adult patients met the eligibility criteria. Of these, 212 (53%) never achieved a seizure-free period of a year or more. The trajectories of 63 patients (16%) had a complex fluctuating trajectory, 62 (15%) had delayed onset of seizure freedom, and 66 (16%) had an early seizure freedom. Independent predictors associated with more favorable outcome trajectories were epilepsy type and length of follow-up. Specifically, compared to patients with focal epilepsy of temporal lobe, patients with focal epilepsy of occipital lobe (OR 3.80, 95% confidence interval [CI] 1.00-14.51, p = 0.04), generalized genetic (OR 3.23, 95% CI 1.88-5.57, p < 0.0001), unclear epilepsy type (OR 3.82, 95% CI 1.53-9.52, p < 0.005), and both focal and generalized epilepsy (OR 11.73, 95% CI 1.69-81.34, p = 0.01) were significantly more likely to experience a better trajectory pattern. SIGNIFI-CANCE: Examination of patterns of seizure trajectory of patients with incident DRE showed that 31% were in continuous seizure freedom at the end of the observation period.
Drug-Resistant Epilepsy in Adults: Outcome Trajectories After Failure of Two Medications.

Drug-Resistant Epilepsy: Is it Really Sometimes RRMS (Relapsing-Remitting Multiple Seizures)?
these studies had several limitations, including relatively short follow-up.
Longer term follow-up of these and similar cohorts revealed a more complex picture of these small but measurable successes (8, 9) . Although these previously DRE patients did have surprisingly high seizure remission rates (estimated cumulative probability of 12-month remission of 34.6% at 7 years in the Callaghan study), longer-term analyses revealed a dynamic process, with patients entering into remission and frequently later experiencing seizure relapses. Choi and coworkers reported an estimated annual probability of seizure relapse of approximately 25%, and a cumulative probability of relapse of 81% by year 5 in a similar population (9) . This pattern was similar to that described in pediatric patients by Berg and coworkers (10) .
As this more dynamic picture of DRE was emerging, a new definition of DRE was put forth by the International League Against Epilepsy (ILAE), which was less restrictive than the requirement of at least monthly seizures used in these cited studies (11) . The ILAE definition includes the possible outcomes of an appropriate antiepileptic drug (AED) trial (seizure freedom, treatment failure, or undetermined) and establishes a definition of seizure freedom: 3 times the longest preintervention interseizure interval or 1 year, whichever is longer. With these parameters established, the definition states that "failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve seizure freedom" constitutes DRE (11) .
It is possible that cohorts identified using the ILAE definition of DRE might look different than those previously discussed. Additionally, prior studies examined prevalence cohorts-those in whom medically refractory epilepsy was prevalent-sampled at various temporal stages of disease. This is potentially an important distinction, as duration of epilepsy is frequently identified as a factor associated with refractoriness.
With this background, Choi et al. set out to follow the trajectory of an incident cohort-one in which DRE had just been established using the ILAE criteria. They retrospectively identified incident cases from a large database at a tertiary epilepsy program. Patients who received surgical or vagus nerve stimulation (VNS) therapy were censored at the date of the procedure. Similar to Brodie et al. (12) , they created an ordinal outcome scale that placed patients into 1 of 4 ranked categories:
• Category 1. Constant seizures (not seizure free for ≥1 year);
• Category 2. Fluctuating course (some seizure-free intervals of ≥1 year, but in relapse at end of study);
• Category 3. Delayed attainment of seizure freedom (seizure freedom attained after >12 months and maintained throughout follow-up);
• Category 4. Early attainment of seizure freedom (seizure freedom attained within the first 12 months and maintained throughout follow-up).
Not surprising, a slight majority of patients (53%) fell into category 1 (consistently refractory). However, a substantial proportion (16%) showed a fluctuating course, 15% required more than 1 year to achieve sustained seizure freedom, and 16% who fulfilled the ILAE definition of DRE achieved sustained seizure freedom within a year of the definition being applied. Thus, a full 31% of this incident cohort had prolonged seizure freedom over a mean duration of more than 3 years. Seizure outcome trajectory was associated with epilepsy syndrome: those with genetic generalized epilepsies (44% consistently seizure free) fared better than those with focal epilepsy (28%), and least successful in achieving good outcomes were those with "encephalopathic generalized" epilepsies (7%). In bivariate analysis, epilepsy type, intellectual disability, epilepsy etiology, and observation time were associated with trajectory outcome, but in multivariate analysis, after adjusting for the confound of time under observation, only the epilepsy type was associated with the outcome trajectory.
What can be concluded from this latest addition to the increasingly nuanced picture of DRE? First and foremost, this information should not take the epilepsy community off message regarding the need for early surgical evaluation of patients who meet criteria for DRE. There is ample evidence that the majority of patients who meet this definition do poorly with subsequent antiseizure medication trials, with either consistently refractory epilepsy or unsustained periods of remission. As is well established, epilepsy surgery in appropriate patients is superior to medical therapy, with a low number-needed-to-treat to demonstrate superiority of surgery. For those who are not epilepsy surgery candidates, the good news is that up to one-third of incident cases of DRE (under the ILAE definition) may achieve a period of sustained seizure freedom, and others may have at least some periods of seizure freedom punctuated by relapses. The outlook appears slightly more optimistic for "newly diagnosed" (incident) DRE than for prevalence cohorts of patients with longstanding DRE.
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